OBJECTIVES: Cervical and vulvar cancers develop through well-defined precursor lesions but their exact pathogenesis is still unknown. The dystroglycan complex is a transmembrane glycoprotein that forms a continuous link from the extracellular matrix to the actin cytoskeleton. Deregulated expression of dystroglycan has been reported in human malignancies and related to tumor differentiation and aggressiveness. In this study, expression of dystroglycan was evaluated in the multistep cervical and vulvar tumorigenesis. METHODS: Expression of the dystroglycan complex was evaluated by immunostaining in lesions representing different stages of vulvar and cervical tumorigenesis using a monoclonal antibody which recognizes carbohydratic epitopes on the alpha-dystroglycan subunit. RESULTS: alpha-dystroglycan was constantly detected in normal cervical epithelium with a mean percentage of positive cells higher than 80%. A progressive significant reduction in the mean percentage of positive cells was observed in low (67%) and high grade SIL (14%) and in invasive carcinomas (2.6%) of the cervix. In cancers, no differences were observed in terms of percentage of positive cells when cases were stratified according with either tumor grade or stage. A progressive significant reduction in the mean percentage of positive cells was also observed from normal vulvar epithelium (90%) to VIN1 (66%), VIN2 (28%) and invasive vulvar carcinomas (22%). No significant decrease in the alpha-dystroglycan staining was observed in squamous cell hyperplasia lesions (85%) while lichen sclerosus displayed a percentage of positive cells (47%) significantly lower than normal epithelium. CONCLUSIONS: Detection of alpha-dystroglycan is frequently lost in human cervical and vulvar tumorigenesis and further studies are warranted to verify whether evaluation of this molecule might serve as marker of risk progression of preneoplastic lesions and to better understand its significance in terms of cancer development.
OBJECTIVES: Cervical and vulvar cancers develop through well-defined precursor lesions but their exact pathogenesis is still unknown. The dystroglycan complex is a transmembrane glycoprotein that forms a continuous link from the extracellular matrix to the actin cytoskeleton. Deregulated expression of dystroglycan has been reported in humanmalignancies and related to tumor differentiation and aggressiveness. In this study, expression of dystroglycan was evaluated in the multistep cervical and vulvar tumorigenesis. METHODS: Expression of the dystroglycan complex was evaluated by immunostaining in lesions representing different stages of vulvar and cervical tumorigenesis using a monoclonal antibody which recognizes carbohydratic epitopes on the alpha-dystroglycan subunit. RESULTS: alpha-dystroglycan was constantly detected in normal cervical epithelium with a mean percentage of positive cells higher than 80%. A progressive significant reduction in the mean percentage of positive cells was observed in low (67%) and high grade SIL (14%) and in invasive carcinomas (2.6%) of the cervix. In cancers, no differences were observed in terms of percentage of positive cells when cases were stratified according with either tumor grade or stage. A progressive significant reduction in the mean percentage of positive cells was also observed from normal vulvar epithelium (90%) to VIN1 (66%), VIN2 (28%) and invasive vulvar carcinomas (22%). No significant decrease in the alpha-dystroglycan staining was observed in squamous cell hyperplasia lesions (85%) while lichen sclerosus displayed a percentage of positive cells (47%) significantly lower than normal epithelium. CONCLUSIONS: Detection of alpha-dystroglycan is frequently lost in human cervical and vulvar tumorigenesis and further studies are warranted to verify whether evaluation of this molecule might serve as marker of risk progression of preneoplastic lesions and to better understand its significance in terms of cancer development.
Authors: Jian Guo Shen; Chao Yang Xu; Xin Li; Ming Jun Dong; Zi Nong Jiang; Jin Wang; Lin Bo Wang Journal: Pathol Oncol Res Date: 2011-06-22 Impact factor: 3.201
Authors: Alison K Esser; Michael R Miller; Qin Huang; Melissa M Meier; Daniel Beltran-Valero de Bernabé; Christopher S Stipp; Kevin P Campbell; Charles F Lynch; Brian J Smith; Michael B Cohen; Michael D Henry Journal: J Biol Chem Date: 2012-12-06 Impact factor: 5.157
Authors: Daniel Beltrán-Valero de Bernabé; Kei-Ichiro Inamori; Takako Yoshida-Moriguchi; Christine J Weydert; Hollie A Harper; Tobias Willer; Michael D Henry; Kevin P Campbell Journal: J Biol Chem Date: 2009-02-24 Impact factor: 5.157
Authors: Michael R Miller; Deqin Ma; James Schappet; Patrick Breheny; Sarah L Mott; Nadine Bannick; Eric Askeland; James Brown; Michael D Henry Journal: Mol Cancer Date: 2015-07-30 Impact factor: 27.401
Authors: Shelly Th McClatchey; Zheng Wang; Lara M Linden; Eric L Hastie; Lin Wang; Wanqing Shen; Alan Chen; Qiuyi Chi; David R Sherwood Journal: Elife Date: 2016-09-23 Impact factor: 8.140